Xiao Hongyi, Gu Xiuxia, Shi Xinyuan, Yu Shiyu, Ji Ruoyi, Ji Fanceng, Nie Peihe
Department of Anesthesiology, Weifang People's Hospital, Weifang, 261041, People's Republic of China.
School of Anaesthesiology, Shandong Second Medical University, Weifang, 261053, People's Republic of China.
Drug Des Devel Ther. 2025 Aug 22;19:7285-7292. doi: 10.2147/DDDT.S542292. eCollection 2025.
This study compared the effects of different body mass indexes (BMI) on the induction dose of remimazolam in patients undergoing gynaecological day surgery, aiming to explore the appropriate weight index of remimazolam for overweight or obese people.
This was a retrospective, observational study based on propensity score matching (PSM). The patients were divided into two groups according to normal BMI boundaries: group N (BMI<24 kg/m²) and group F (BMI≥24 kg/m²). The primary observation of the study was the anesthetic induction dose per kg of remimazolam calculated on the basis of total body weight (TBW), ideal body weight (IBW), lean body weight (LBW) and corrected body weight (CBW).
A total of 250 patients were included in the analysis. After PSM, 94 patients were finally included in each group. The primary observation: there was a significant difference between the two groups in the induction dose per kg of TBW and IBW (=0.001), but not in the induction dose per kg of LBW and CBW (>0.05). The Secondary observation:the time to loss of consciousness was shorter in group F than in group N (=0.030), but there was no significant difference in recovery time (=0.868). There were also no significant differences between the two groups in perioperative adverse effects and changes in circulating blood pressure before and after induction (>0.05). In addition, the induction dose of remimazolam per kg calculated based on TBW exhibits a negative correlation with BMI (r=-0.362, =0.001).
When calculated based on TBW, the induction dose of remimazolam per kilogram (mg/kg) was lower in overweight or obese patients compared to normal-weight patients. For these patients, we recommend using CBW for dose calculation when applying the 0.2-0.4 mg/kg dosing regimen.
本研究比较了不同体重指数(BMI)对妇科日间手术患者瑞马唑仑诱导剂量的影响,旨在探索超重或肥胖人群瑞马唑仑的合适体重指数。
这是一项基于倾向评分匹配(PSM)的回顾性观察研究。根据正常BMI界限将患者分为两组:N组(BMI<24 kg/m²)和F组(BMI≥24 kg/m²)。本研究的主要观察指标是基于总体重(TBW)、理想体重(IBW)、瘦体重(LBW)和校正体重(CBW)计算的每千克瑞马唑仑的麻醉诱导剂量。
共250例患者纳入分析。PSM后,每组最终纳入94例患者。主要观察指标:两组每千克TBW和IBW的诱导剂量有显著差异(=0.001),但每千克LBW和CBW的诱导剂量无显著差异(>0.05)。次要观察指标:F组意识消失时间短于N组(=0.030),但恢复时间无显著差异(=0.868)。两组围手术期不良反应及诱导前后循环血压变化也无显著差异(>0.05)。此外,基于TBW计算的每千克瑞马唑仑诱导剂量与BMI呈负相关(r=-0.362,=0.001)。
基于TBW计算时,超重或肥胖患者每千克瑞马唑仑的诱导剂量低于正常体重患者。对于这些患者,在应用0.2 - 0.4 mg/kg给药方案时,我们建议使用CBW进行剂量计算。